Ways2Well Review
GLP-1 weight-loss telehealth · Independently scored 4.4/10
Ways2Well falls below our bar on medical oversight. Read the breakdown below before you give it money.
Covered by the plan
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
No insurance needed · Vetted by our editors
Standalone pricing for GLP-1 weight loss is absent from the live site as of July 2026, kept behind a consult and the membership. Brigham Buhler founded this lab-driven longevity and telehealth membership, which places compounded GLP-1 therapy, semaglutide with a reference to tirzepatide, next to hormone optimization, peptides and bloodwork. A clinician-protocol and membership structure governs the GLP-1 side, and ReviveRX, the sister compounding pharmacy, fills what is written. Coverage keeps expanding and is never fully listed.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Vetted alternatives to Ways2Well
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Ways2Well at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Pricing model
- Flat — dose increases don't raise the monthly price
- What's included
- Medication · Consult · Shipping
- FDA status
- No FDA warning letter on record
How Ways2Well scores
Six columns, each one computed from something Ways2Well has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where it publishes nothing, that absence is what gets scored. Every seller in the register goes through the same six columns.
Value25%
3.0/10No monthly price is published at all, so value cannot be measured against the register. Capped rather than scored.
Effectiveness25%
5.0/10Publishes no medication list or price, so what is prescribed here cannot be established. Held at the midpoint — this is a gap in the record, not a finding about the drugs.
User Experience15%
5.0/10Where this seller first shows a price is not recorded yet, so the signup is unscored and sits at the midpoint.
Trust & Safety15%
4.0/10does not name a dispensing pharmacy; withholds price until after the intake. Our verification confidence is medium.
Accessibility10%
5.0/10Publishes no list of states served, so coverage cannot be confirmed either way. Capped at the midpoint — this measures disclosure, not reach.
Support10%
5.0/10No published price, so what a price would include cannot be assessed. Held at the midpoint.
A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →
What we checked on Ways2Well
Last checked July 2026- Established what the monthly figure covers, and what it leaves out
- Searched our FDA enforcement register for this operator
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below. Editorial confidence in this data: medium.
GLP-1 medications Ways2Well offers
Each one has its own guide: how the molecule works, the dosing schedule, the side effects that show up in practice, and what the trials actually measured.
In its favor
- The monthly price is recorded as flat across doses, so it does not climb as the dose is titrated up
- The monthly figure covers medication, consult, shipping
- No FDA warning letter matched this operator when we searched our enforcement register
Against it
- No state list is on record here, so whether it serves your state cannot be confirmed from this page
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
What Ways2Well charges
Ways2Well does not publish a standing monthly price. That is a choice, and it means you cannot compare it against anything until you have gone through an intake and been quoted. When you get that quote, ask specifically for the ongoing monthly figure and what it includes — not the first-month rate, and not a program total divided by its length.
What Ways2Well dispenses
Ways2Well prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the pair carrying the strongest published outcome data.
What we could verify
Ways2Well publishes little that can be checked from outside an intake. We searched the federal warning-letter record for this operator and came back with nothing. How we weigh oversight, disclosure and price evidence is set out in our scoring methodology.
Who should look elsewhere
- You want the FDA-approved pen specifically. Nothing here is the approved finished product.
- You need to compare prices before committing time to an intake — there is no published figure to compare.
- You need to bill insurance. Like most of this market, this is cash-pay.
It fits if
- you want the price to stop moving as your dose climbs
Our read
We cannot tell you whether Ways2Well is priced well, because it does not say. That is not automatically disqualifying — plenty of legitimate operators quote after intake — but it does mean the comparison has to happen after you have spent the time, which is the wrong order for the buyer. CoreAge Rx is the nearest comparison we track, and worth reading alongside this.
The Bottom Line
Ways2Well falls below our bar on medical oversight. Read the breakdown below before you give it money.
Before you pay Ways2Well
Check today's price, then book the free consultation.
Where Ways2Well is the wrong choice
No seller in this register suits every reader, and saying otherwise would be the easiest way to sell one. On these four counts another entry does better.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
Cited across this Ways2Well review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
See Ways2Well's current pricing
The free consultation is where you learn whether you qualify, and what it costs today.